Title: Cross-sectional and Longitudinal Associations Between Circadian Alignment and Cardiovascular-Kidney-Metabolic Syndrome in US Adults

Running title: Associations of Circadian Alignment and CKM risk and outcomes

Word count: 2993

Author information

Bolin Li [1,†], Xinping Kang [2,†], Yushan Liu [3],Li Ma [6], Qing Zhang [1], Lele Cheng [4], Kai Lan[1], Yongxin Yang [1], Jialing He [1],Miaomiao Cao[4], Zhen Zhang [1], Rong Jie [5]*

[1] Department of Cardiology, The Third People's Hospital of Chengdu, Affiliated Hospital of SouthwestJiaotong University, Chengdu, 610014, Sichuan, China

[2] Dermatology, Xi'an Jiaotong University First Affiliated Hospital, Xi'an, Shaanxi 710004, China

[3] Xi'an Jiaotong University, Xi'an, Shaanxi 710004, China

[4] Department of Medical Imaging, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, , Shaanxi 710004, China

[5] The Affiliated Hospital of Shaanxi University of Chinese Medicine, Xianyang, Shaanxi 712046, China

[6] Intensive Care Unit, Bazhong Central Hospital, Bazhong, 636000, Sichuan, China

[†]Denotes joint first author

[*]Denotes joint corresponding author

Correspondence

Rong Jie, The Affiliated Hospital of Shaanxi University of Chinese Medicine, Xianyang, Shaanxi 712046, China. E-mail: 13186255110@163.com

Zhen Zhang, Department of Cardiology, The Third People's Hospital of Chengdu, Affiliated Hospital of Southwest Jiaotong University, Chengdu, 610014, Sichuan, China. E-mail: zhangzhen@swjtu.edu.cn

Miaomiao Cao, Department of Medical Imaging, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710004, China. E-mail: xjtucm@163.com

Abstract

BACKGROUND AND AIMS: Cardiovascular-kidney-metabolic (CKM) syndrome is a novel consensus defined by its multi-systemic and progressive nature. Circadian rhythm is a critical modulator of metabolic health. However, no previous studies assessed the associations between circadian alignment and CKM risk and outcomes.

Objective: To investigate associations between circadian light-activity synchronization (phasor parameters) and CKM syndrome prevalence and outcomes.

METHOD: This analysis utilized 2011-2014 NHANES data to examine adults (≥20 years) with cardiovascular-kidney-metabolic risk profiles. The circadian alignment evaluates the circadian light-activity synchronization through phasor analysis, including assessing phasor magnitude and acrophase. These parameters are

subsequently categorized into quintiles for further study. Cross-sectional and longitudinal models were implemented to evaluate associations with CKM risk and adverse outcomes.

RESULTS: 7,493 participants, representing 152,571,804 US adults (median 6.83-year follow-up). Participants with the shortest magnitude, characterized by the least overlap between light and activity cycles, not only have the highest risk of CKM (odds ratio [OR] 1.61, 95% CI 1.19–2.16) but also showed high all-cause mortality ([aHR] 1.84, 95% CI 1.37–2.47) and cardiovascular mortality (SHR 2.10, 95%CI 1.31–3.36). We observed a potential linear negative correlation between continuous phasor magnitude and the risk of CKM, as well as adverse outcomes (P-overall <0.001). Similar correlations were found in CVD, CKD, and DM separately. Males and older adults had elevated CKM incidence and all-cause/cardiovascular mortality versus their female/younger counterparts. However, there was no statistical significance between phasor acrophase and CKM risk and adverse outcomes.

CONCLUSION: Individuals with lower phasor magnitude，characterized by the least overlap between light and activity cycles，tend to have higher risks for CKM syndrome and adverse outcomes. These findings underscore quantifying circadian as a modifiable target for CKM primary prevention.

Introduction

Cardiovascular-kidney-metabolic (CKM [1]) syndrome stresses the

[1] CKM: Cardiovascular-kidney-metabolic syndrome

pathophysiological interplay between heart disease, kidney disease, and metabolic risk factors(1), affecting 90% of U.S. adults (15% stage 3-4, 2011-2020)(2). CKM syndrome results in a great economic burden and has emerged as the primary cause of mortality in 2021(3), necessitating early risk screening.

Circadian rhythm operates on a roughly 24-hour cycle, coordinating the timing of physiological processes to keep synchrony with environmental cues, primarily the light-dark cycle. These oscillations regulate sleep architecture, hormone release(4), metabolism(5,6), eating habits(7), or digestion. Its disruption from lifestyle, shift work, or genetic factors triggers systemic desynchronization, elevating risks of metabolic-cardiovascular-renal disorders(8,9).

Diabetes mellitus and metabolic syndrome patients exhibit disrupted circadian rhythms, which correlate with elevated risks of hypertension(10) and cardiovascular complications(8). Also, researchers demonstrated the impacts of circadian rhythm disruption on renal physiology, including glomerular filtration efficiency, tubular reabsorption, abnormal sodium handling, renin-angiotensin-aldosterone system (RAAS [2]) dynamics, and compromising systemic blood pressure regulation(9), indicating bidirectional circadian-CKM interactions. Population-level quantification of intricate relationship between circadian rhythm disruptions and CKM may provide strategies for modifiable prevention of CKM syndrome.

Here, we collected data from the NHANES study cohort, using phasor analysis to examine the associations of circadian alignment and CKM risk and outcomes, aiming

[2] RAAS: renin-angiotensin-aldosterone system

to identify the prospective targets for CKM prevention and management.

Method

Data source and study population

Data in the present investigation were retrieved from the National Health and Nutrition Examination Survey (NHANES[3]), which is a national, serial, one-time probability sampling design program to track health and nutrition patterns across age groups. Approval for the NHANES protocol was granted by the National Center for Health Statistics Ethics Review Board. The ethics approval was not required for this study because it was a secondary analysis based on a publicly available database and did not include identified personal information. The present research adhered to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) for reporting observational studies in epidemiology, specifically for cross-sectional studies.

NHANES data from the two-year cycles of 2011-2012，2013-2014 are screened in this study. Of all 19,931 participants in the 2011-2014 NHANES survey, we excluded those aged＜20 years and lacking information of CKM syndrome determination, survival outcome, and light and/or activity data. Consequently, a total of 7493 participants were enrolled.

Phasor analysis

Light exposure and physical activity patterns were objectively monitored were measured by physical activity monitoring devices in NHANES survey[(11)]. Phasor

[3] NHANES: National Health and Nutrition Examination Survey

analysis evaluates the 24-hour light intensity and motility fluctuations by two variables including phasor magnitude and acrophase(12). Light exposure has a nonlinear impact on the human circadian system (13). To address circadian photoreception nonlinearity, light intensity data were adjusted via logistic curves with a 10,000 lux biological ceiling.

Circadian stimulation (CS[4]) metrics from Daysimeter recordings underwent logistic transformation to map threshold-to-saturation responses(12). Behavioral entrainment was assessed through circular cross-correlations, revealing timing-related relationships. Normalization involved dividing by total samples, adjusting by standard deviations, ensuring correlation coefficients range from -1 to 1(14). This analysis provides a robust framework for understanding circadian stimulation's impact on behavioral responses, utilizing statistical methods to extract meaningful correlations from complex datasets. The phasor magnitude indicates the extent of alignment between an individual's light-dark cycle and his/her activity cycle, while the phasor acrophase reflects the temporal relationship between the two cycles.

Assessment of CKM conditions

In the current study, CKM conditions include chronic kidney disease (CKD[5]) ,cardiovascular disease (CVD[6]) , diabetes mellitus (DM[7]) as recommended(15). CVD was defined as history of coronary heart disease, angina, heart attack, heart failure,

[4] CS: circadian stimulation
[5] CKD: chronic kidney disease
[6] CVD: cardiovascular disease
[7] DM: diabetes mellitus

and stroke. CKD risk is classified based on estimated glomerular filtration rate(GFR[8]) classification and albumin levels, with moderate risk serving as the threshold for albuminuria as suggested(1,16), with moderate risk serving as the threshold for defining CKD as a binary variable Diabetes mellitus was determined as HbA1c≥6.5%, fasting glucose>7.0mmol/L, self-reported diagnosis of diabetes, or usage of diabetes medications. CKM was defined as the presence of at least one comorbid CKM condition(15).

Outcome

This study assessed three endpoints: all-cause, cardiovascular, and premature mortality. Total mortality (national registry-confirmed fatalities, regardless of cause) and cardiovascular mortality (ICD-10 I00-I99: ischemic heart disease [I20-I25], myocardial infarction [I21-I22], heart failure [I50], cerebrovascular events [I60-I69]) were defined per 2019 ICD-10 criteria. Premature death denoted fatalities before age 70.

Covariates

Potential confounders, including age as a continuous variable, gender (female or male), racial and ethnic background (Hispanic; non-Hispanic Black, non-Hispanic White, and other [multiracial and any race other than Black or White]), smoking behavior (current, former, <100 cigarettes in life or never smoker), and alcohol use (nondrinker, < 1/week, 1/week to 1/day, 1/day above), education (less than high school,

[8] GFR: glomerular filtration rate

high school graduate, some college, college graduate and above or others), marital status(marital, unmarried or unknown), household income(<20000, 20000-44900, 45000-74900, >75000 and unknown), and Body Mass Index(BMI)(<18.5, 18.5-25, 25-30, ≥30). All the covariates are self-reported, mutually exclusive categories. Demographic characteristics and lifestyle habits were obtained by personal interview, and BMI was derived from physical measurements at the Mobile Examination Center.

Statistic analysis

Analytical approaches incorporated CDC-recommended NHANES sampling weights (WTINT2YR) to account for complex survey design effects, including cluster sampling and non-response bias. All statistical procedures adhered to CDC analytic guidelines for complex survey data. Quintiles grouped phasor magnitude and angle to characterize the research population. Continuous measures reported as weighted means ± standard error (SE)(normal) or medians with 95% confidence intervals (CIs)(skewed), categorical variables as adjusted proportions. Group comparisons utilized Wald-F, Kruskal Wallis, and Rao-Scott χ^2 tests. The cross-sectional analysis of the relationship between phasor magnitude (continuous variables) and CKM risk utilizes binary logistic weighted regression. Longitudinal analyses addressed cause-specific mortality rate, based on Cox proportional hazards regression models Model 1 adjusted for age and sex in logistic regression (adjusted for the number of CKM conditions in cox regression). Model 2 further controlled for other confounding variables such as race and ethnicity, education level, marital status, and household

income. Model 3 further accounted for smoking, BMI, and alcohol consumption. Additionally, the Fine and Gray method was applied to estimate the competing risks in cardiovascular mortality. And follow-up period had a median of 6.83 years (interquartile range [IQR] 5.75–7.92). To assess the potential linear relationship between phasor magnitude and CKM, as well as adverse outcomes, restricted cubic splines were applied, with adjustment for the covariates in Model 3.

All our statistical analyses used R4.4.1 (R Foundation for Statistical Computing, Vienna, Austria) statistical software, except for competing risk regression analysis was conducted using STATA 17.0 based on the Fine and Gray model.

Results

Baseline characteristics of participants

Descriptive data grouped by phasor magnitude quintile are presented in **Table 1** below. The final enrolled participants (n=7493) were representative of 152,571,804 US adults. Approximately 48% of them were male and 68% were non-Hispanic whites, with a weighted median age of 50 years. The median phasor magnitude and acrophase were 0.36 (0.28-0.43) and 0.69(-0.13-1.56). In the present study, the proportion of CKM, CKD, CVD, DM was 31% (n=8,285,175), 11%(n=4,544,837), 17% (n=3,019,140), 15% (n=4,063,762), respectively. Additionally, while the proportion of young adults aged 20-39 years, non-Hispanic blacks, and non-married status were prone to negatively related with phasor magnitude, that of older adults aged over 60 years, non-Hispanic whites, married status showed a positive correlation with phasor magnitude.

Association between circadian alignment and CKM risk

Firstly, we evaluated the relationship of phasor variables (magnitude and acrophase) and CKM risk. There was no statistically difference of CKM prevalence between different magnitude quintiles groups, despite Q1 group has the highest proportion (Table 1). Three logistic regression models were built to identified the association between phasor magnitude and CKM risk (**Figure 2A**). Model 1(adjusted for age and sex) shows stepwise increased trends for CKM risks with reduced phasor magnitude (P trends < 0.001). Specifically, participants in Q1 group (the shortest magnitude) are 80% (odds ratio [OR] 1.80, 95% CI 1.41-2.31) more likely to have CKM compared with the reference group (Q5 group). Although further adjusted for potential confounders slightly attenuated the association in model 2 and 3, the first quartile (Q1) group always demonstrated highest risk of CKM, with an OR of 1.61 (95% CI: 1.19–2.16) in the fully adjusted model 3. **Figure 2B-D** also revealed that shorter phasor magnitude exhibited a higher risk for each separate CKM condition (CKD, CVD, DM) (P<0.001). However, the impacts of phasor magnitude on CVD (OR 1.66, 95% CI 1.16-2.37) and CKD risk (OR 1.62,95% CI 1.14-2.30) are greater than on DM (OR 1.41, 95% CI 1.06-1.87) in the fully adjusted model 3.

The restricted cubic spline (RCS) analysis revealed a linear negative correlation between continuous phasor magnitude and the risk of CKM (P-overall <0.001, P-nonlinearity = 0.48), as illustrated in **Figure 1A** based on Model3(adjusted for age and sex, race, ethnicity, education level, marital status, household income, smoking, alcohol

consumption, and BMI). Similar correlations were observed in CVD (P-overall <0.001, P-nonlinearity = 0.43), CKD (P-overall <0.001, P-nonlinearity = 0.43), and DM(P-overall <0.001, P-nonlinearity = 0.14) (Figures 1B-D). Furthermore, subgroup analyses were conducted to identify the correlations between continuous phasor magnitude and the risks of CKM and each separate CKM conditions, stratified by sex (female, male) and age (grouped by 20-39, 40-59, 60 and beyond). The curves showed similar linear negative correlations across different subgroups, as shown in Figure 1. Interestingly, male and older individuals with short phasor magnitude were more likely to have CKM and each separate CKM condition, compared with their female and younger counterparts.

There was no statistical significance between acrophase quintiles and the CKM risk, as well as CVD, CKD, and DM risks in the adjusted logistic regression models (**sup. Fig3**). However, RCS curves indicated U-shaped associations between acrophase and CKM (P-overall <0.001, P-nonlinearity = 0.19), CVD (P-overall <0.0001, P-nonlinearity = 0.23), in which small and large acrophase were related to higher CKM and CVD risks compared with median acrophase. Moreover, acrophase was negatively correlated with CKD risk (P-overall <0.001, P-nonlinearity = 0.50), and positively correlated with DM risk (P-overall <0.001, P-nonlinearity = 0.52) (sup. Fig2). Similar to phasor magnitude, male and older individuals exhibited higher risks of CKM and each separate CKM conditions, compared with their female and younger counterparts in the subgroup analyses (**sup. Fig2**).

Association between circadian alignment and adverse outcomes

Secondly, we explored the relationships between phasor variables (magnitude and acrophase) and adverse outcomes (all-cause mortality, cardiovascular mortality, and premature mortality). The cumulative hazard function (CHF) were used to assess risks for adverse outcomes by magnitude quartiles groups are shown in **Figure 3**. During a median follow-up of 6.67 years [interquartile range (5.67, 7.92)], short phasor magnitude was associated with a poor prognosis, especially for the first magnitude quartile (Q1) group. **The supplementary Figure 1** heat map reveals that mortality increases with the number and overlap of diseases and decreases with the phasor magnitude overall. Additionally, the percentages of each adverse outcomes seemed to be increased with the number of CKM conditions, but irrespective of type of CKM overlaps (Fig3).

In the Cox proportional hazards models, Q1 group was independently related to high all-cause mortality (adjusted hazard ratio [aHR] 1.45, 95% CI 1.07–1.98) and cardiovascular mortality (aHR 2.14, 95% CI 1.39–3.18), after adjusted the number of CKM conditions in model 1, and this relationship remained after adjustment for other confounders in mode 2 and model 3 (**Figure 4a**). Notably, Q1 group is 110% (aHR 2.10, 95%CI 1.374–3.36) more likely to die from cardiovascular disease compared to Q5 group in the fully adjusted model 3 (**Figure 5B**). No statistical significance was identified in the association between magnitude quartiles and premature mortality (aHR 1.80, 95% CI 0.94–3.34) (Figure 5C-D). RCS analyses in figure 3 further supported the linear negative correlations between continuous phasor magnitude and adverse

outcomes, including all-cause mortality (P-overall <0.001, P-nonlinearity = 0.16), cardiovascular mortality (P-overall <0.001, P-nonlinearity = 0.39), and premature mortality (P-overall <0.001, P-nonlinearity = 0.69). When stratifying the study population by sex, age, and number of CKM conditions, similar trends were found for all-cause mortality and cardiovascular mortality, but varied for and premature mortality (Figure 3). Male, older individuals and the more CKM overlap conferred higher risk of all-cause mortality and cardiovascular mortality, compared with their female and younger counterparts as well as those with less CKM overlap. Furthermore, the largest gap of adverse outcomes between sex, age group, and number of CKM overlap was all found in those with short magnitude.

However, there was no statistical significance between phasor acorphase and adverse outcomes (**sup Fig5**) mortality, despite a linear correlation was found for all-cause mortality (P-nonlinearity=0.90), cardiovascular mortality (P-nonlinearity=0.30), and premature mortality (P-nonlinearity=0.43) (**sup Fig 4**).

Discussion

Based on the literature review, this is the first cross-sectional and longitudinal study to investigate whether circadian alignment related to the CKM risk and outcomes in US adults by using a nationally representative sample. Results indicated that phasor magnitude (coupling extent of activity and light) negatively related to the risks of CKM and adverse outcomes mortality (all-cause and cardiovascular mortality). Besides, Males and older adults had elevated CKM incidence and all-cause/cardiovascular

mortality versus female/younger counterparts. Additionally, higher all-cause and cardiovascular mortality frequencies among participants with greater numbers of coexisting CKM conditions. The largest gaps were observed in participants with short phasor magnitude.

In essence, circadian dysfunction and CKM are both significant public health issues(17,18)mediated by bidirectional interactions between endogenous physiology (cellular/behavioral processes) and exogenous environmental cues(19–21). Whereas existing research predominantly examines isolated circadian metrics (light-dark cycles or activity-rest patterns) or transient misalignments (e.g., chronotypes/social jet lag)(20), our study employs phasor analysis to quantify continuous light-activity cycle coupling, a validated biomarker of circadian dysregulation (11,14,22). Our observations align with Xiao et al.'s report that reduced phasor magnitude predicts incident diabetes mellitus, correlating with elevated HOMA-IR, OGTT, and fasting insulin levels (11). Growing evidence also showed that circadian dysfunction has an impact on CVD and CKD. Two large-scale population studies revealed insomnia associated with an increased risk for acute myocardial infarction[23] and incident heart failure(24). Nighttime artificial light exposure and late-night dietary intake exhibit quantifiable associations with heightened metabolic syndrome predisposition and elevated cardiovascular morbidity risk(25). A Mendelian randomization study including 465,814 UK Biobank participants demonstrated short sleep duration (<6 hours) was significantly related to a higher risk of CKD stages 3–5[(26). Critically, diminished phasor magnitude predicts graded risks of CVD, CKD, and CKM severity, underscoring

its translational utility for identifying high-risk populations.

Existing studies have examined inadequate sleep to elevated all-cause mortality (HR 1.23, 95% CI 1.13–1.34) and cardiovascular deaths (HR 1.39, 1.19–1.62) versus restorative sleep, with low physical activity exacerbating risks in a UK Biobank study (27). This association can be exacerbated by low physical activity. Further, in diabetic populations, healthy sleep patterns similarly reduce all-cause mortality(28), aligning with our finding that minimal phasor magnitude (light-activity misalignment) independently predicts higher all-cause/cardiovascular mortality. A Pooled analysis of 958,674 subjects across 16 cohorts confirms rotating/night shifts elevate all-cause/cardiovascular mortality versus daytime schedules(29). Furthermore, our analysis demonstrated a similar inverse association between phasor magnitude and mortality rates within the CKM cohort, a pattern consistently observed in CVD-related comorbidities and additional CKM-related health states, CKD. Wu et al. suggested that disorders including DM, coronary artery disease, and depression, partially mediate the causal relationship that short sleep duration was negatively correlated with lifespan(30). Our findings further identifies that circadian misalignment (shorter phasor magnitude) and CKM multimorbidity jointly amplify mortality risk.

Interestingly, male and older individuals were more likely to have CKM as well as present with higher risks of all-cause and cardiovascular mortality, especially for those with short magnitude. Indeed, sex and age-related disparities for circadian and CKM have been well-recognized. The ‘‘lateness’’ of chronotypes reaches a maximum around age 20, and then shift earlier with increasing age. In comparison with women, men

show their ‘‘lateness’’ of chronotypes later and maintain most of their adulthood. Individuals aged over 60 years old mostly showed early chronotype(20,31) . Men and people aged over 65 have higher prevalence of advanced CKM stages(2) . Although the underlying mechanisms have not been elucidated, interaction of multiple factors, such as hormonal levels, 24-hour gene expression rhythms, and social factors et al., might involve in the different vulnerabilities to circadian dysfunction, CKM risk and outcomes between sex and age.

Regarding phasor acorphase, there was no statistical significance between acorphase and CKM risk and outcomes. Because the acrophase of light and activity peaks may be shifted forward or backward. Positive and negative acrophases may offset each other, thereby weakening their association with diseases and adverse outcomes.

Our study has some limitations. A key limitation of this observational design is the inability to establish causality between CKM-related risk factors and the coherence of the activity cycle and light cycle. Some studies also show cardiovascular disease can lead to circadian rhythm disorder, and vice versa. Second, we did not rule out all potential confounding factors that could influence the results, like seasons, genetic susceptibility, and underlying health conditions. Third, individuals with more severe diseases and hospitalized patients may have regular routines due to physician recommendations, leading to high magnitude; however, their disease severity and mortality rates are elevated. Fourth, we didn’t consider other daily activities such as physical exercise and meal timing, which are likely related to health status.

Reduced alignment between circadian rhythms and daily activity patterns

independently predicts incident cardiometabolic-kidney multimorbidity (CKM) and adverse outcomes. Our findings, integrating novel phasor analysis with competing-risk models, position circadian optimization as a modifiable target for primary prevention—particularly in males and older adults, who face disproportionate CKM burdens.

Public health strategies should prioritize scalable circadian interventions (e.g., community-based light exposure guidelines, age-tailored physical activity programs) to curb the rising global burden of metabolic-kidney disorders. Mechanistic trials evaluating circadian-aligned therapies in high-risk populations are urgently needed.

Funding

This study was supported by the National Natural Science Foundation of China (No.82200500) and (No.82400407).

Acknowledgements

This work was supported by the National Natural Science Foundation of China (No.82200500) and (No.82400407). The authors would like to thank Cheng lele, for his help in the Methodology.

Declaration

1. Competing interests

The authors declare no competing interests, including financial benefits, non-monetary associations, or institutional engagements that could directly/indirectly influence the research objectives, analytical processes, or conclusions outlined in this

work.

2. Ethics approval

All data in this study are included in NHANES. National Center for Health Statistics (NCHS) Ethics Review Board (ERB) provides centralized ethical oversight of all human subject protections in NCHS research initiatives and did not require additional ethical review by the investigator's affiliated institution.

3. Consent

Written consent documentation was secured from all enrolled subjects through standardized protocols that explicitly authorized anonymized data utilization and inclusion in scholarly publications.

4. Data

All data generated or analysed during this study are included in NHANES from the 2011–2012 and 2013–2014 cycles. Which is available for publication at *https://www.cdc.gov/nchs/nhanes/index.htm*

5. Authors' contribution statements

designed research: Rong Jie, Bolin Li

conducted research: Rong Jie, Miaomiao Cao

Formal analysis: Zhen Zhang, Kai Lan, Ma Li

Vusualisation: Yushan Liu, Yongxin Yang

funding acquisition: Lele Cheng, Qing Zhang

project administration: Zhen Zhang

software: Rong Jie, Jialing He

Methodology: Bolin Li, Xinping Kang, Lele Cheng

Writing-original draft: Xinping Kang, Bolin Li

Review &editing: Miaomiao Cao, Bolin Li

References

1. Ndumele CE, Rangaswami J, Chow SL, Neeland IJ, Tuttle KR, Khan SS, et al. Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association. Circulation. 2023 Nov 14;148(20):1606–35.

2. Aggarwal R, Ostrominski JW, Vaduganathan M. Prevalence of Cardiovascular-Kidney-Metabolic Syndrome Stages in US Adults, 2011-2020. JAMA. 2024 Jun 4;331(21):1858–60.

3. Mortality in the United States, 2021 [Internet]. [cited 2024 Jun 15]. Available from: https://stacks.cdc.gov/view/cdc/122516

4. Alvord VM, Kantra EJ, Pendergast JS. Estrogens and the circadian system. Semin Cell Dev Biol. 2022 Jun;126:56–65.

5. Bass J, Takahashi JS. Circadian integration of metabolism and energetics. Science. 2010 Dec 3;330(6009):1349–54.

6. Shi S qun, Ansari T, McGuinness OP, Wasserman DH, Johnson CH. Circadian disruption leads to insulin resistance and obesity. Curr Biol [Internet]. 2013 Mar 4 [cited 2024 Jun 15];23(5):372–81. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3595381/

7. Rao F, Xue T. Circadian-independent light regulation of mammalian metabolism. Nat Metab. 2024 Jun;6(6):1000–7.

8. Manoogian ENC, Zadourian A, Lo HC, Gutierrez NR, Shoghi A, Rosander A, et al. Feasibility of time-restricted eating and impacts on cardiometabolic health in 24-h shift workers: The Healthy Heroes randomized control trial. Cell Metab. 2022 Oct 4;34(10):1442-1456.e7.

9. Mohandas R, Douma LG, Scindia Y, Gumz ML. Circadian rhythms and renal pathophysiology. J Clin Invest. 2022 Feb 1;132(3):e148277.

10. Škrlec I, Talapko J, Džijan S, Cesar V, Lazić N, Lepeduš H. The Association

between Circadian Clock Gene Polymorphisms and Metabolic Syndrome: A Systematic Review and Meta-Analysis. Biology (Basel). 2021 Dec 24;11(1):20.

11. Xiao Q, Durbin J, Bauer C, Yeung CHC, Figueiro MG. Alignment Between 24-h Light-Dark and Activity-Rest Rhythms Is Associated With Diabetes and Glucose Metabolism in a Nationally Representative Sample of American Adults. Diabetes Care. 2023 Dec 1;46(12):2171–9.

12. Rea MS, Bierman A, Figueiro MG, Bullough JD. A new approach to understanding the impact of circadian disruption on human health. J Circadian Rhythms. 2008 May 29;6:7.

13. Rea MS, Figueiro MG, Bierman A, Bullough JD. Circadian light. Journal of Circadian Rhythms [Internet]. 2010 Feb 13 [cited 2024 Dec 15];8(0). Available from: https://jcircadianrhythms.com/articles/10.1186/1740-3391-8-2

14. Miller D, Bierman A, Figueiro M, Schernhammer E, Rea M. Ecological measurements of light exposure, activity, and circadian disruption. Light Res Technol [Internet]. 2010 Sep [cited 2024 Nov 24];42(3):271–84. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3596178/

15. Lassen MCH, Ostrominski JW, Claggett BL, Packer M, Zile M, Desai AS, et al. Cardiovascular-kidney-metabolic overlap in heart failure with preserved ejection fraction: Cardiac structure and function, clinical outcomes, and response to sacubitril/valsartan in PARAGON-HF. European Journal of Heart Failure [Internet]. 2024 Aug 1 [cited 2024 Nov 21];26(8):1762–74. Available from: https://onlinelibrary.wiley.com/doi/10.1002/ejhf.3304

16. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024 Apr;105(4S):S117–314.

17. Di H, Guo Y, Daghlas I, Wang L, Liu G, Pan A, et al. Evaluation of Sleep Habits and Disturbances Among US Adults, 2017-2020. JAMA Netw Open. 2022 Nov 1;5(11):e2240788.

18. Zhu R, Wang R, He J, Wang L, Chen H, Niu X, et al. Prevalence of Cardiovascular-Kidney-Metabolic Syndrome Stages by Social Determinants of Health. JAMA Netw Open. 2024 Nov 4;7(11):e2445309.

19. Zielinska-Dabkowska KM, Schernhammer ES, Hanifin JP, Brainard GC. Reducing nighttime light exposure in the urban environment to benefit human health and society. Science. 2023 Jun 16;380(6650):1130–5.

20. Gentry NW, Ashbrook LH, Fu YH, Ptáček LJ. Human circadian variations. J Clin Invest. 2021 Aug 16;131(16):e148282.

21. Patke A, Young MW, Axelrod S. Molecular mechanisms and physiological importance of circadian rhythms. Nat Rev Mol Cell Biol. 2020 Feb;21(2):67–84.

22. Gan Y, Yang C, Tong X, Sun H, Cong Y, Yin X, et al. Shift work and diabetes mellitus: a meta-analysis of observational studies. Occup Environ Med. 2015 Jan;72(1):72–8.

23. Laugsand LE, Vatten LJ, Platou C, Janszky I. Insomnia and the risk of acute myocardial infarction: a population study. Circulation. 2011 Nov 8;124(19):2073–81.

24. Zielinska-Dabkowska KM, Schernhammer ES, Hanifin JP, Brainard GC. Reducing nighttime light exposure in the urban environment to benefit human health and society. Science. 2023 Jun 16;380(6650):1130–5.

25. Meléndez-Fernández OH, Liu JA, Nelson RJ. Circadian Rhythms Disrupted by Light at Night and Mistimed Food Intake Alter Hormonal Rhythms and Metabolism. Int J Mol Sci. 2023 Feb 8;24(4):3392.

26. Park S, Lee S, Kim Y, Lee Y, Kang MW, Kim K, et al. Short or Long Sleep Duration and CKD: A Mendelian Randomization Study. J Am Soc Nephrol. 2020 Dec;31(12):2937–47.

27. Huang BH, Duncan MJ, Cistulli PA, Nassar N, Hamer M, Stamatakis E. Sleep and physical activity in relation to all-cause, cardiovascular disease and cancer mortality risk. Br J Sports Med. 2022 Jul;56(13):718–24.

28. Li J, Yin J, Luo Y, Ma T, He L, Xie H, et al. Association of healthy sleep pattern with the risk of cardiovascular disease and all-cause mortality among people with diabetes: A prospective cohort study. Diabetes Res Clin Pract. 2022 Apr;186:109822.

29. Su F, Huang D, Wang H, Yang Z. Associations of shift work and night work with risk of all-cause, cardiovascular and cancer mortality: a meta-analysis of cohort studies. Sleep Med. 2021 Oct;86:90–8.

30. Wu Y, Zhang CY, Liu X, Wang L, Li M, Li Y, et al. Shared genetic architecture and causal relationship between sleep behaviors and lifespan. Transl Psychiatry. 2024 Feb 22;14(1):108.

31. Roenneberg T, Kuehnle T, Juda M, Kantermann T, Allebrandt K, Gordijn M, et al. Epidemiology of the human circadian clock. Sleep Med Rev. 2007 Dec;11(6):429–38.

Figure legend

Figure 1. Restricted cubic spline curves for association between phasor magnitude and CKM* risk (A-C), CVD* risk (D-F), CKD* risk (G-I) and DM* risk(J-L). All plots are performed using multivariate logistic regression based on Model 3. The hazard ratio is represented by a red line and the 95% confidence interval is represented by the shaded area.The right two plots of each row illustrate subgroup analyses adjusted for sex and age.

CKM: cardiovasculer-kidney-metabolic syndrome

CKD: chronic-kidney disease

CVD: cardiovascular disease

DM: diabetes mellitus

Figure 2. Association between phasor magnitude and CKM risk (A), CKD risk (B), CVD risk (C) and DM risk(D). All plots are performed using multivariate logistic regression based on Model 1 (age and sex), Model 2 (additional race and ethnicity, education level, marital status, and household income), Model 3(additional smoking, alcohol consumption, and BMI). ORs and 95% CI are presented comparing with Q1 (referrence group).

BMI: body mass index

Figure 3. Cumulative hazard function curves competing risks regression analysis under

Fine and Gray models estimates for selected endpoints, cardiovascular mortality(B), cox (all-cause mortality(A), and premature mortality(C)) by phasor magnitude.

Figure 4. RCS curves for association between phasor magnitude and all-cause mortality (A-D), cardiovascular mortality (E-H), and premature mortality (I-L). All plots are performed using multivariate Cox proportional hazards regression based on Model 3. The hazard ratio is represented by a red line and the 95% confidence interval is represented by the shaded area.

The right 3 plots of each row illustrate subgroup analyses stratified by sex, age and the number of ckm conditions.

Figure 5. Association between phasor magnitude and all-cause mortality (A), cardiovascular mortality (B), premature mortality (C) . Plots are performed using multivariate Cox proportional hazards regression - Model 1 (age and sex) , Model 2 (additional race and ethnicity, education level, marital status, and household income), Model 3(additional smoking, alcohol consumption, and BMI). HRs and 95% CI are presented comparing with Q1 (referrence group).

Table1

	Phasor variable[1]					
	Q1	Q2	Q3	Q4	Q5	*P* value
Phasor magnitude,median(IQR)	0.20 (0.16, 0.23)	0.29 (0.27, 0.31)	0.35 (0.33, 0.36)	0.41 (0.39, 0.42)	0.48 (0.46, 0.51)	<0.001
Phasor Acrophase,median(IQR)	0.91 (-0.69, 2.34)	0.89 (0.09, 1.79)	0.82 (-0.01, 1.57)	0.62 (-0.07, 1.44)	0.46 (-0.14, 1.10)	<0.001
Age(%)						<0.001
20-39	9,816,924 (37%)	10,096,082 (35%)	9,013,348 (31%)	8,673,912 (28%)	7,930,076 (24%)	
40-59	10,234,358 (39%)	10,961,091 (38%)	10,966,586 (38%)	12,945,061 (41%)	13,104,961 (40%)	
60+	6,284,067 (24%)	7,520,784 (26%)	8,907,132 (31%)	9,731,169 (31%)	11,896,744 (36%)	
gender(%)						0.011
female	12,276,843 (47%)	14,207,489 (50%)	16,174,014 (56%)	17,280,928 (55%)	17,108,556 (52%)	
male	14,058,505 (53%)	14,370,467 (50%)	12,713,052 (44%)	14,069,213 (45%)	15,823,226 (48%)	
Race and ethnicity(%)						<0.001
Hispanic	1,403,312 (5.3%)	1,683,691 (5.9%)	1,795,080 (6.2%)	2,015,566 (6.4%)	1,862,293 (5.7%)	
Non-Hispanic Black	4,633,728 (18%)	3,668,122 (13%)	3,263,076 (11%)	2,669,875 (8.5%)	1,489,527 (4.5%)	
Non-Hispanic White	16,255,486 (62%)	18,621,752 (65%)	19,341,389 (67%)	22,047,092 (70%)	24,573,591 (75%)	
Other	4,042,823 (15%)	4,604,392 (16%)	4,487,521 (16%)	4,617,609 (15%)	5,006,370 (15%)	
education level(%)						<0.001
college graduate or above	8,758,461 (33%)	10,244,292 (36%)	9,749,853 (34%)	9,642,357 (31%)	8,258,101 (25%)	
high school graduate	5,085,669 (19%)	5,082,898 (18%)	5,959,426 (21%)	6,300,516 (20%)	8,371,905 (25%)	
Less than high school	3,463,955 (13%)	3,320,454 (12%)	4,365,792 (15%)	5,434,091 (17%)	6,520,862 (20%)	
some college	8,987,676 (34%)	9,925,815 (35%)	8,811,994 (31%)	9,964,724 (32%)	9,780,913 (30%)	
missing	39,588	4,496	0	8,454	0	
marriage(%)						<0.001
Marital	12,353,211 (47%)	15,173,493 (53%)	16,238,690 (56%)	19,465,343 (62%)	21,392,410 (65%)	
not married	13,982,138 (53%)	13,404,463 (47%)	12,648,376 (44%)	11,884,798 (38%)	11,532,385 (35%)	

missing	0	0	0	0	6,986	
household income(%)						0.032
<20,000	4,419,523 (17%)	4,105,840 (15%)	4,199,173 (15%)	4,352,958 (14%)	4,503,324 (14%)	
20,000–44,900	8,237,377 (32%)	6,925,288 (25%)	7,761,724 (28%)	8,376,772 (28%)	10,186,478 (32%)	
45,000–74,900	4,098,034 (16%)	5,950,178 (21%)	5,626,140 (20%)	6,601,103 (22%)	6,604,534 (21%)	
75,000+	8,917,827 (35%)	10,733,356 (39%)	10,366,385 (37%)	10,965,539 (36%)	10,847,880 (34%)	
missing	662,587	863,293	933,644	1,053,769	789,566	
BMI(%)[2]						0.4
elevated	19,249,109 (74%)	20,222,947 (71%)	20,915,749 (73%)	23,649,332 (76%)	24,043,734 (73%)	
normal	6,900,390 (26%)	8,176,237 (29%)	7,857,435 (27%)	7,654,959 (24%)	8,888,047 (27%)	
missing	185,850	178,771	113,881	45,851	0	
Smoke(%)						<0.001
current	6,123,432 (23%)	5,161,282 (18%)	4,695,329 (16%)	5,719,500 (18%)	6,329,003 (19%)	
former	4,543,657 (17%)	6,724,608 (24%)	7,680,548 (27%)	8,605,511 (27%)	9,770,327 (30%)	
no	15,659,549 (59%)	16,682,649 (58%)	16,506,229 (57%)	17,017,758 (54%)	16,818,045 (51%)	
missing	8,710	9,416	4,959	7,373	14,407	
Drink(%)						<0.001
1/day above	624,593 (2.4%)	1,128,046 (3.9%)	841,568 (2.9%)	1,777,901 (5.7%)	2,871,126 (8.7%)	
1/week to <1/day	7,238,767 (27%)	8,801,689 (31%)	9,184,558 (32%)	9,414,505 (30%)	9,883,451 (30%)	
<1/week	9,522,003 (36%)	10,324,606 (36%)	9,562,381 (33%)	10,371,964 (33%)	10,477,470 (32%)	
no	8,949,986 (34%)	8,323,616 (29%)	9,298,558 (32%)	9,785,772 (31%)	9,699,734 (29%)	
CKM_stage						0.15
Stage-0	2,718,809 (10%)	3,310,526 (12%)	2,808,886 (9.7%)	2,711,976 (8.7%)	2,888,008 (8.8%)	
Stage-1	5,702,962 (22%)	5,637,875 (20%)	5,238,536 (18%)	6,141,368 (20%)	6,010,415 (18%)	
Stage-2	12,770,224 (48%)	14,857,412 (52%)	15,902,197 (55%)	17,527,027 (56%)	19,051,928 (58%)	
Stage-3	1,911,948 (7.3%)	1,911,131 (6.7%)	1,795,716 (6.2%)	2,108,797 (6.7%)	1,730,290 (5.3%)	

Stage-4	3,231,405 (12%)	2,861,011 (10%)	3,141,730 (11%)	2,860,974 (9.1%)	3,251,141 (9.9%)	
CVD[3]	3,231,405 (12%)	2,861,011 (10%)	3,141,730 (11%)	2,860,974 (9.1%)	3,251,141 (9.9%)	0.3
CKD[4]	4,316,430 (17%)	4,269,661 (15%)	4,155,896 (14%)	4,682,719 (15%)	4,260,640 (13%)	0.4
DM	4,068,029 (15%)	4,301,013 (15%)	4,037,728 (14%)	4,533,223 (14%)	4,199,979 (13%)	0.4
Follow time (month)	81 (70, 95)	80 (70, 95)	82 (69, 95)	85 (71, 96)	84 (71, 97)	0.12

1. All percentages and medians (IQRs) are weighted using sample weight

2. normal body mass index (BMI) (<23 kg/m2 for individuals with Asian ethnicity and <25 kg/m2 for other racial and ethnic groups)

elevated BMI (≥23 kg/m2 for individuals with Asian race and >25 kg/m2 for all other race and ethnic groups)

3. CVD was identified based on self-reported established cardiovascular disease (coronary heart disease, angina, heart attack, heart failure, and stroke)

4. CKD was identified based on Kidney Disease Improving Global Outcomes (KDIGO) criteria, with CKD risk as moderate-to-very-high risk.


A
advanced CKM prevalence
P−overall <.0001
P−non−linear = 0.15
OR (95% CI)
B
advanced CKM prevalence
age.group
20−39
40−59
60+
C
advanced CKM prevalence
Gender
female
male
D
CVD
P−overall <.0001
P−non−linear = 0.61
E
CVD
F
CVD
G
CKD
P−overall <.0001
P−non−linear = 0.58
H
CKD
I
CKD
J
DM
P−overall <.0001
P−non−linear = 0.31
K
DM
L
DM
Magnitude


A
Group
OR.95.CI.
P.trend
Advanced CKM
Model1
Q5 (0.438, 0.643] Ref <0.001
Q4 (0.378, 0.438] 1.28 (0.96−1.72)
Q3 (0.321, 0.378] 1.49 (1.04−2.14)
Q2 (0.251, 0.321] 1.72 (1.21−2.43)
Q1 (0.005, 0.251] 2.52 (1.86−3.41)
Model2
Q5 (0.438, 0.643] Ref <0.001
Q4 (0.378, 0.438] 1.36 (0.99−1.88)
Q3 (0.321, 0.378] 1.64 (1.09−2.46)
Q2 (0.251, 0.321] 1.83 (1.29−2.59)
Q1 (0.005, 0.251] 2.52 (1.87−3.4)
Model3
Q5 (0.438, 0.643] Ref <0.001
Q4 (0.378, 0.438] 1.29 (0.87−1.89)
Q3 (0.321, 0.378] 1.53 (0.98−2.38)
Q2 (0.251, 0.321] 1.64 (1.09−2.46)
Q1 (0.005, 0.251] 2.25 (1.59−3.19)
0.5 1 3.5
Lower risk Higher risk
B
Group
OR (95% CI)
P.trend
CKD
Model1
Q5 (0.438~0.643] 1(ref) <0.001
Q4 (0.378~0.438] 1.33(0.98−1.8)
Q3 (0.322~0.378] 1.32(0.94−1.86)
Q2 (0.251~0.322] 1.5(1.15−1.94)
Q1 (0.0063~0.251] 1.82(1.37−2.4)
Model2
Q5 (0.438~0.643] 1(ref) <0.001
Q4 0.378,0.4381 1.33(0.98−1.8)
Q3 (0.322~0.378] 1.27(0.9−1.79)
Q2 (0.251~0.322] 1.42(1.08−1.86)
Q1 (0.0063~0.251] 1.63(1.21−2.2)
Model3
Q5 (0.438~0.643] 1(ref) <0.001
Q4 0.378,0.4382 1.29(0.91−1.84)
Q3 (0.322~0.378] 1.23(0.83−1.83)
Q2 (0.251~0.322] 1.35(1−1.81)
Q1 (0.0063~0.251] 1.62(1.14−2.3)
0.5 1 2.5
Lower risk Higher risk
C
Group
OR.95.CI.
P.trend
CVD
Model1
Q5 (0.438, 0.643] Ref <0.001
Q4 (0.378, 0.438] 1.03 (0.71−1.49)
Q3 (0.321, 0.378] 1.31 (0.93−1.85)
Q2 (0.251, 0.321] 1.33 (0.98−1.81)
Q1 (0.005, 0.251] 1.86 (1.44−2.4)
Model2
Q5 (0.438, 0.643] Ref <0.001
Q4 (0.378, 0.438] 1.08 (0.73−1.61)
Q3 (0.321, 0.378] 1.42 (0.98−2.05)
Q2 (0.251, 0.321] 1.39 (1.02−1.9)
Q1 (0.005, 0.251] 1.87 (1.44−2.43)
Model3
Q5 (0.438, 0.643] Ref <0.001
Q4 (0.378, 0.438] 1.03 (0.66−1.62)
Q3 (0.321, 0.378] 1.36 (0.9−2.07)
Q2 (0.251, 0.321] 1.25 (0.86−1.83)
Q1 (0.005, 0.251] 1.66 (1.24−2.23)
0.5 1 2.5
Lower risk Higher risk
D
Group
OR.95.CI.
P.trend
DM
Model1
Q5 (0.438, 0.643] Ref <0.001
Q4 (0.378, 0.438] 1.28 (0.97−1.67)
Q3 (0.321, 0.378] 1.27 (0.96−1.69)
Q2 (0.251, 0.321] 1.52 (1.18−1.95)
Q1 (0.005, 0.251] 1.64 (1.28−2.11)
Model2
Q5 (0.438, 0.643] Ref <0.001
Q4 (0.378, 0.438] 1.35 (1.02−1.79)
Q3 (0.321, 0.378] 1.31 (0.96−1.78)
Q2 (0.251, 0.321] 1.63 (1.26−2.11)
Q1 (0.005, 0.251] 1.63 (1.27−2.11)
Model3
Q5 (0.438, 0.643] Ref <0.001
Q4 (0.378, 0.438] 1.24 (0.92−1.67)
Q3 (0.321, 0.378] 1.17 (0.85−1.61)
Q2 (0.251, 0.321] 1.44 (1.09−1.9)
Q1 (0.005, 0.251] 1.47 (1.11−1.93)
0.5 1 2.5
Lower risk Higher risk


A
Cox proportional hazards regression (all-cause mortality)
Magnitude5Q
Q1
Q2
Q3
Q4
Q5
Cumulative Hazard
0
.02
.04
.06
.08
0
50
100
Time (month)
B
Competing-risks regression (Cardiovascular mortality)
Magnitude5Q
Q1
Q2
Q3
Q4
Q5
Cumulative Incidence
0
.005
.01
.015
.02
0
50
100
Time(month)
C
Cox proportional hazards regression (premature mortality)
Magnitude5Q
Q1
Q2
Q3
Q4
Q5
Cumulative Hazard
0
.005
.01
.015
.02
.025
0
50
100
Time (month)


A
All-cause mortality
B
All−cause mortality
C
All−cause mortality
D
All−cause mortality
E
Cardiovascular mortality
F
Cardiovascular mortality
G
Cardiovascular mortality
H
Cardiovascular mortality
I
Premature mortality
J
Premature mortality
K
Premature mortality
L
Premature mortality
HR (95% CI)
Magnitude
Age.group
20−39
40−59
60+
age.group
Gender
female
male
advanced CKM
advanced_CKM
0
1


A
Group
HR.95.CI.
P.trend
All-cause mortality
Model1
Q5 (0.438, 0.643] Ref <0.01
Q4 (0.378, 0.438] 1.16 (0.79−1.69)
Q3 (0.321, 0.378] 1 (0.73−1.37)
Q2 (0.251, 0.321] 1.17 (0.83−1.67)
Q1 (0.005, 0.251] 1.46 (1.11−1.94)
Model2
Q5 (0.438, 0.643] Ref <0.001
Q4 (0.378, 0.438] 1.26 (0.87−1.84)
Q3 (0.321, 0.378] 1.05 (0.76−1.46)
Q2 (0.251, 0.321] 1.25 (0.86−1.8)
Q1 (0.005, 0.251] 1.65 (1.24−2.21)
Model3
Q5 (0.438, 0.643] Ref <0.001
Q4 (0.378, 0.438] 1.25 (0.89−1.77)
Q3 (0.321, 0.378] 1.05 (0.78−1.41)
Q2 (0.251, 0.321] 1.25 (0.86−1.84)
Q1 (0.005, 0.251] 1.75 (1.35−2.26)
0
1
2.5
Lower risk
Higher risk
B
Group
SHR.95.CI.
P.trend
Cardiovascular mortality
Model1
Q5 (0.438, 0.643] Ref <0.001
Q4 (0.378, 0.438] 1.28 (0.8−2.04)
Q3 (0.321, 0.378] 1.39 (0.89−2.19)
Q2 (0.251, 0.321] 1.42 (0.9−2.24)
Q1 (0.005, 0.251] 1.84 (1.21−2.81)
Model2
Q5 (0.438, 0.643] Ref <0.001
Q4 (0.378, 0.438] 1.31 (0.82−2.1)
Q3 (0.321, 0.378] 1.42 (0.89−2.26)
Q2 (0.251, 0.321] 1.5 (0.95−2.39)
Q1 (0.005, 0.251] 2.02 (1.31−3.11)
Model3
Q5 (0.438, 0.643] Ref <0.01
Q4 (0.378, 0.438] 1.31 (0.81−2.1)
Q3 (0.321, 0.378] 1.42 (0.89−2.27)
Q2 (0.251, 0.321] 1.41 (0.88−2.25)
Q1 (0.005, 0.251] 1.89 (1.22−2.93)
0
1
3
Lower risk
Higher risk
C
Group
HR.95.CI.
P.trend
Premature mortality
Model1
(0.438, 0.643] Ref <0.05
(0.378, 0.438] 1.27 (0.61−2.65)
(0.321, 0.378] 0.83 (0.44−1.56)
(0.251, 0.321] 1.16 (0.61−2.18)
(0.005, 0.251] 1.77 (0.95−3.29)
Model2
(0.438, 0.643] Ref ns
(0.378, 0.438] 1.45 (0.72−2.92)
(0.321, 0.378] 0.88 (0.45−1.73)
(0.251, 0.321] 1.32 (0.69−2.53)
(0.005, 0.251] 1.61 (0.85−3.02)
Model3
(0.438, 0.643] Ref ns
(0.378, 0.438] 1.45 (0.71−2.93)
(0.321, 0.378] 0.89 (0.47−1.66)
(0.251, 0.321] 1.42 (0.73−2.74)
(0.005, 0.251] 1.69 (0.93−3.05)
0
1
4
Lower risk
Higher risk